Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1574-1578, 2023.
Article
de Zh
| WPRIM
| ID: wpr-1010008
Bibliothèque responsable:
WPRO
ABSTRACT
Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Tumeurs hématologiques
/
Antigènes CD38
/
Anticorps monoclonaux
/
Myélome multiple
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2023
Type:
Article